ADB-BUTINACA (also known as ADMB-BINACA using EMCDDA naming standards [3]) is a synthetic cannabinoid compound which has been sold as a designer drug. [4][5][6][7][8] It is a potent CB 1 agonist, with a binding affinity of 0.29nM for CB1 and 0.91nM for CB2, and an EC 50 of 6.36 nM for CB1. [9][10][11][12][13][14][15]

use as a primary urinary biomarker. ADB-BUTINACA binds to CB1 and CB2 receptors with high affinity (Ki = 0.299 nM and 0.912 nM, respectively) and is a potent full agonist at both receptors, with an efficacy (Emax) ranging from 101% to 290% depending on …

Nov 22, 2021 · We discuss the metabolism of ADB-BUTINACA and identification of its metabolites using human hepatocytes (HHeps) and the detection of ADB-BUTINACA and its metabolites in authentic blood and urine samples from 13 routine toxicology cases in …

We report the increasing prevalence of the synthetic cannabinoid receptor agonist (SCRA) ADB-BUTINACA (N- [1-amino-3,3-dimethyl-1-oxobutan-2-yl]-1-butyl-1H-indazole-3-carbox-amide). ADB-BUTINACA was first detected in a seizure in Sweden in 2019, and we report its detection in 13 routine Swedish forensic toxicology cases soon after.

MDMB‐4en‐PINACA manifested the most potent and sustained effects, followed by ADB‐4en‐PINACA, ADB‐BINACA and ADB‐BICA. Additionally, the cannabinoid receptor 1 (CB1R) antagonist AM251 suppressed the effects induced by acute administration of the substances.

First detected in a seizure in Sweden in 2019 followed by its detection in 13 routine toxicology screenings ADB-BUTINICA is a novel synthetic cannabinoid which in January 2021 was detected in Synthetic Cannabinoid Receptor Agonist (SCRA) infused papers seized from Scottish prisons.

VIENNA, Austria – November 2023: The decision adopted by the Commission on Narcotic Drugs (CND) during its 66th Session, from 13 to 17 March 2023, to add ADB-BUTINACA, alpha-PiHP and 3-methylmethcathinone to Schedule II of the Convention on Psychotropic Substances of 1971 entered into force on 13 November 2023.

We discuss the metab-olism of ADB-BUTINACA and identification of its metabolites using infused papers which are often detected by prison staff screening incoming prison mail using ion mobility spectrometry.13,14We present human hepatocytes (HHeps) and …

Nov 22, 2023 · VIENNA, Austria – November 2023: The decision adopted by the Commission on Narcotic Drugs (CND) during its 66th Session, from 13 to 17 March 2023, to add ADB-BUTINACA, alpha-PiHP and 3-methylmethcathinone to Schedule II of the Convention on Psychotropic Substances of 1971 entered into force on 13 November 2023.

Jan 11, 2024 · ADB-Butinaca is a synthetic cannabinoid, belonging to a class of compounds designed to mimic the effects of THC, the active ingredient in cannabis. These substances are often sprayed onto...